Alemtuzumab in allogeneic hematopoetic stem cell transplantation

Bibliography

• Gooley TA, Chien JW, Pergam SA, Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;11:2091-101
   Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R, Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. N Engl J Med 2010;363:2091-101
   PubMedGoogle Scholar
• Wolff D, Gerbitz A, Ayuk F, Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010;16:1611-28
   PubMed Web of Science ®Google Scholar
• Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005;360:1707-11
   PubMed Web of Science ®Google Scholar
• Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-204
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Carabasi MH, Castro-Malaspina H, T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998;91:1083-90
   PubMed Web of Science ®Google Scholar
• Hale G, Zhang MJ, Bunjes D, Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-90
   PubMed Web of Science ®Google Scholar
• Martinez C, Urbano-Ispizua A, Rozman C, Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999;27:561-8
   PubMed Web of Science ®Google Scholar
• Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009;144:818-31
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S, Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205-13
   PubMed Web of Science ®Google Scholar
• Risitano AM, Selleri C, Serio B, Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010;148:791-6
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
   PubMed Web of Science ®Google Scholar
• Tan HP, Donaldson J, Basu A, Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009;9:355-66
   PubMed Web of Science ®Google Scholar
• Pearl JP, Parris J, Hale DA, Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-74
   PubMed Web of Science ®Google Scholar
• Bloom DD, Chang Z, Fechner JH, CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793-802
   PubMed Web of Science ®Google Scholar
• Trzonkowski P, Zilvetti M, Chapman S, Homeostatic repopulation by CD28–CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008;8:338-47
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R, Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071-8
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-25
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Ruiz-Arguelles GJ, Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:10-15
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Lifely MR, Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-40
   PubMed Web of Science ®Google Scholar
• Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-12
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-91
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Abramson JS, Pinkus GS, Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-9
   PubMed Web of Science ®Google Scholar
• Albitar M, Do KA, Johnson MM, Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004;101:999-1008
   PubMed Web of Science ®Google Scholar
• Matthews K, Lim Z, Afzali B, Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica 2009;94:956-66
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260-70
   PubMed Web of Science ®Google Scholar
• Penack O, Fischer L, Stroux A, Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:377-83
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Reagan JL, Heller G, Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003;101:1422-9
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien SM, Cortes JE, Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98:773-8
   PubMed Web of Science ®Google Scholar
• Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476-83
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Roth A, Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217-24
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634-45
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang M, Goldman CK, Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003;63:6453-7
   PubMed Web of Science ®Google Scholar
• Lin TS, Flinn IW, Modali R, FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005;105:289-91
   PubMed Web of Science ®Google Scholar
• Rebello P, Cwynarski K, Varughese M, Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001;3:261-7
   PubMed Web of Science ®Google Scholar
• Morris EC, Rebello P, Thomson KJ, Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003;102:404-6
   PubMed Web of Science ®Google Scholar
• Tholouli E, Liakopoulou E, Greenfield HM, Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. Br J Haematol 2008;142:318-20
   PubMed Web of Science ®Google Scholar
• Brett S, Baxter G, Cooper H, Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996;88:13-19
   PubMed Web of Science ®Google Scholar
• Bertz H, Spyridonidis A, Wasch R, A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 2009;15:1563-70
   PubMed Web of Science ®Google Scholar
• Spyridonidis A, Liga M, Triantafyllou E, Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. Bone Marrow Transplant: published online 20 December 2010; doi: 10.1038/bmt.2010.308
   Google Scholar
• Chakraverty R, Orti G, Roughton M, Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010;116:3080-8
   PubMed Web of Science ®Google Scholar
• Bokhari S, Das-Gupta E, Russell N, Byrne J. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab. Bone Marrow Transplant 2008;42:281-2
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR, Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-55
   PubMed Web of Science ®Google Scholar
• Oshima K, Kanda Y, Nakahara F, Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies. Am J Hematol 2006;81:875-9
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J, Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-91
   PubMed Web of Science ®Google Scholar
• Delgado J, Thomson K, Russell N, Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006;107:1724-30
   PubMed Web of Science ®Google Scholar
• Juliusson G, Theorin N, Karlsson K. et al. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006;37:503-10
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V, Hale G, Waldmann H. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Transplantation 1999;67:620-6
   PubMed Web of Science ®Google Scholar
• Jacobs P, Wood L. Immunohematopoietic stem cell transplantation: introduction and 35 years of development in South Africa–the historical and scientific perspective. Bone Marrow Transplant 2008;42(Suppl 1):S125-32
   PubMedGoogle Scholar
• Barge RM, Starrenburg CW, Falkenburg JH, Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath “in the bag” as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006;37:1129-34
   PubMed Web of Science ®Google Scholar
• von dem Borne PA, Beaumont F, Starrenburg CW, Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006;91:1559-62
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V, du Toit C, McDonald A. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD. Bone Marrow Transplant 2009;43:779-85
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, MacDonald D, Hale G, T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003;121:109-18
   PubMed Web of Science ®Google Scholar
• Mead AJ, Thomson KJ, Morris EC, HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 2010;115:5147-53
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Koh LP, Long GD, Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-7
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Dev P, Long GD, Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. Bone Marrow Transplant 2009;43:327-33
   PubMed Web of Science ®Google Scholar
• Ho AY, Pagliuca A, Kenyon M, Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;104:1616-23
   PubMed Web of Science ®Google Scholar
• Tauro S, Craddock C, Peggs K, Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005;23:9387-93
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S, Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728-38
   PubMed Web of Science ®Google Scholar
• van Besien K, Kunavakkam R, Rondon G, Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009;15:610-17
   PubMed Web of Science ®Google Scholar
• Lim ZY, Ho AY, Ingram W, Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006;135:201-9
   PubMed Web of Science ®Google Scholar
• Lim ZY, Pearce L, Ho AY, Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007;138:517-26
   PubMed Web of Science ®Google Scholar
• Malladi RK, Peniket AJ, Littlewood TJ, Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 2009;43:709-15
   PubMed Web of Science ®Google Scholar
• Craddock C, Nagra S, Peniket A, Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010;95:989-95
   PubMed Web of Science ®Google Scholar
• Patel B, Kirkland KE, Szydlo R, Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009;94:1399-406
   PubMed Web of Science ®Google Scholar
• Freytes CO, Loberiza FR, Rizzo JD, Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797-803
   PubMed Web of Science ®Google Scholar
• Morris E, Thomson K, Craddock C, Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865-71
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Morris EC, Bloor A, Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27:426-32
   PubMed Web of Science ®Google Scholar
• Cook G, Smith GM, Kirkland K, Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British society for blood and marrow transplantation. Biol Blood Marrow Transplant 2010;16:1419-27
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Morris EC, Milligan D, T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010;28:3695-700
   PubMed Web of Science ®Google Scholar
• Morris E, Mackinnon S. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci 2005;32:73-83
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-16
   PubMed Web of Science ®Google Scholar
• Peggs KS, Sureda A, Qian W, Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007;139:70-80
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Peggs KS, Smith P, Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008;41:765-70
   PubMed Web of Science ®Google Scholar
• Peggs KS, Kayani I, Edwards N, Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971-8
   PubMed Web of Science ®Google Scholar
• Hari P, Carreras J, Zhang MJ, Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14:236-45
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Horowitz S, Artz AS, T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma 2011;52:214-22
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL, BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428-34
   PubMed Web of Science ®Google Scholar
• Ingram W, Devereux S, Das-Gupta EP, Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008;141:235-43
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438-47
   PubMed Web of Science ®Google Scholar
• Crawley C, Szydlo R, Lalancette M, Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-76
   PubMed Web of Science ®Google Scholar
• Poire X, Artz A, Larson RA, Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma 2009;50:85-91
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R, Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105:4532-9
   PubMed Web of Science ®Google Scholar
• Siegal D, Xu W, Sutherland R, Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008;42:51-6
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Kang EM, Fitzhugh CD, Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-17
   PubMed Web of Science ®Google Scholar
• Chewning JH, Castro-Malaspina H, Jakubowski A, Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007;13:1313-23
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Luznik L, Muth M, Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant 2009;43:477-80
   PubMed Web of Science ®Google Scholar
• Martinez C, Solano C, Ferra C, Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a Phase II study. Biol Blood Marrow Transplant 2009;15:639-42
   PubMed Web of Science ®Google Scholar
• Schnitzler M, Hasskarl J, Egger M, Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15:910-18
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, Ruiz-Delgado GJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:7-9
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH, Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103:1548-56
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Artz AS, Stock W, Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007;40:1027-32
   PubMed Web of Science ®Google Scholar
• van Besien K, Dew A, Lin S, Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009;50:1809-17
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669-73
   PubMed Web of Science ®Google Scholar
• Kroger N, Shaw B, Iacobelli S, Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005;129:631-43
   PubMed Web of Science ®Google Scholar
• Norlin AC, Remberger M. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2010;86:57-66
   PubMed Web of Science ®Google Scholar
• Soiffer R, LeRademacher J, Ho V, Impact of in vivo T-cell depletion on outcome of reduced intensity conditioning (RIC) hematopoetic cell transplantation (HCT) for hematological malignancies. Blood (ASH Annual Meeting Abstracts) 2010;116: abstract 2305
   Google Scholar
• Landgren O, Gilbert ES, Rizzo JD, Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992-5001
   PubMed Web of Science ®Google Scholar
• Lowdell MW, Craston R, Ray N, The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant 1998;21:679-86
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Schwarck S, Stroux A, Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol;91:877-85
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-63
   PubMed Web of Science ®Google Scholar
• Lamba R, Carrum G, Myers GD, Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 2005;36:797-802
   PubMed Web of Science ®Google Scholar
• Lim ZY, Cook G, Johnson PR, Results of a Phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res 2009;33:244-9
   PubMed Web of Science ®Google Scholar
• Kline J, Pollyea DA, Stock W, Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006;37:307-10
   PubMed Web of Science ®Google Scholar
• O'Donnell PH, Swanson K, Josephson MA, BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant 2009;15:1038-48 e1
   PubMed Web of Science ®Google Scholar
• Carpenter B, Haque T, Dimopoulou M, Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 2010;90:564-70
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Milligan DW, Pillay D, Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839-42
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002;100:1619-27
   PubMed Web of Science ®Google Scholar